NASDAQ:RARX - Ra Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.37 -0.05 (-0.44 %)
(As of 07/17/2018 09:54 AM ET)
Previous Close$11.35
Today's Range$11.35 - $11.37
52-Week Range$4.78 - $17.90
Volume200 shs
Average Volume323,137 shs
Market Capitalization$360.97 million
P/E Ratio-4.75
Dividend YieldN/A
Beta1.75
Ra Pharmaceuticals logoRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Debt-to-Equity RatioN/A
Current Ratio15.37
Quick Ratio15.37

Price-To-Earnings

Trailing P/E Ratio-4.75
Forward P/E Ratio-4.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.93 million
Price / Sales74.47
Cash FlowN/A
Price / CashN/A
Book Value$3.06 per share
Price / Book3.72

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-54,430,000.00
Net MarginsN/A
Return on Equity-66.83%
Return on Assets-60.01%

Miscellaneous

Employees63
Outstanding Shares32,290,000
Market Cap$360.97

The Truth About Cryptocurrencies

Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) released its earnings results on Wednesday, May, 9th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.05. View Ra Pharmaceuticals' Earnings History.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Ra Pharmaceuticals.

What price target have analysts set for RARX?

6 Wall Street analysts have issued 1-year price objectives for Ra Pharmaceuticals' stock. Their predictions range from $14.00 to $31.00. On average, they anticipate Ra Pharmaceuticals' share price to reach $21.20 in the next year. This suggests a possible upside of 85.6% from the stock's current price. View Analyst Ratings for Ra Pharmaceuticals.

What is the consensus analysts' recommendation for Ra Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Ra Pharmaceuticals' key competitors?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas A. Treco, CEO, Pres, Co-Founder & Director (Age 60)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 54)
  • Dr. Simon Read Ph.D., Chief Scientific Officer (Age 47)
  • Dr. Ramin Farzaneh-Far M.D., FACC, Chief Medical Officer (Age 41)
  • Ms. Kerry Black M.S., M.B.A., Exec. Director of Operations

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Has Ra Pharmaceuticals been receiving favorable news coverage?

News stories about RARX stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ra Pharmaceuticals earned a news impact score of 0.13 on Accern's scale. They also gave news headlines about the company an impact score of 46.10 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $11.42.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $360.97 million and generates $4.93 million in revenue each year. The company earns $-54,430,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Ra Pharmaceuticals employs 63 workers across the globe.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.